Autoimmune Diseases  >>  Admelog (insulin lispro biosimilar)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Admelog (insulin lispro biosimilar) / Sanofi
NCT02273258: A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes

Completed
1
30
Europe
SAR342434, Insulin Lispro
Sanofi
Type 1 Diabetes
07/13
07/13
NCT02603510: Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion

Completed
1
27
US
SAR342434, insulin lispro, Humalog
Sanofi
Type 1 Diabetes Mellitus
04/16
04/16

Download Options